Product Use Citations
-
Zhang Z, et al. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1
Theranostics. 2016, 6(2):219-30.
I-BET151 (GSK1210151A) purchased from Selleck.
-
Tranchant R, et al. Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma.
Clin Cancer Res. 2016, 10.1158/1078-0432.
PF-04691502 , Verteporfin purchased from Selleck.
-
Carniti C, et al. Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects
Clin Cancer Res. 2015, 21(16):3740-9.
S-Ruxolitinib (INCB018424) purchased from Selleck.
-
Mao Y, et al. Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma
Clin Cancer Res. 2016, 22(15):3849-59.
-
Kuiatse I, et al. Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia
Clin Cancer Res. 2015, 21(11):2538-45.
Bortezomib (PS-341) , Eprodisate disodium and R788 (Fostamatinib) Disodium purchased from Selleck.
-
Hedayati M, et al. Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation
Clin Cancer Res. 2016, 22(13):3310-9.
Lovastatin purchased from Selleck.
-
Ercan D, et al. EGFR mutations and resistance to Irreversible pyrimidine based EGFR inhibitors.
Clin Cancer Res. 2015, 10.1158/1078-0432.CCR-14-2789.
Gefitinib (ZD1839) , CL-387785 (EKI-785) and Afatinib (BIBW2992) purchased from Selleck.
-
Niederst MJ, et al. The allelic context of the C797S mutation acquired upon treatment with third generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies.
Clin Cancer Res. 2015, 10.1158/1078-0432.CCR-15-0560.
Afatinib (BIBW2992) , Gefitinib (ZD1839) and WZ4002 purchased from Selleck.
-
Huang P, et al. Hepatitis B Virus X Protein (HBx) Is Responsible for Resistance to Targeted Therapies in Hepatocellular Carcinoma: Ex Vivo Culture Evidence
Clin Cancer Res. 2015, 21(19):4420-30.
GW5074 purchased from Selleck.
-
Kobayashi Y, et al. EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
Clin Cancer Res. 2015, 21(23):5305-13.
Dacomitinib (PF299804, PF299) , Rociletinib (CO-1686, AVL-301) and Neratinib (HKI-272) purchased from Selleck.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- 173
- 174
AllPage:
Page:
